From the Iowa Department of Public Health (IDPH)
IDPH Media Release
FOR IMMEDIATE RELEASE
Contact: Sarah Ekstrand
(Des Moines, IA) Following the announcement today (Friday) that the Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) have lifted the pause on the administration of the Johnson & Johnson vaccine, the Iowa Department of Public Health (IDPH) recommends that any vaccine provider in the state who has available Johnson & Johnson vaccine resume administration, effective immediately.
The pause was recommended after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Johnson & Johnson vaccine.
The CDC and FDA issued the following:
• Use of the Johnson & Johnson COVID-19 vaccine should be resumed in the United States.
• The FDA and CDC have confidence that this vaccine is safe and effective in preventing COVID-19.
• The FDA has determined that the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.
• At this time, the available data suggest that the chance of TTS occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.
• Health care providers administering the vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers)external icon and Fact Sheet for Recipients and Caregiversexternal icon, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Johnson & Johnson COVID-19 Vaccine.
More information on the CDC website here.